



**NEW MEDICINE APPLICATIONS BROUGHT TO THE
BORDERS FORMULARY COMMITTEE (BFC)
AND AREA DRUG & THERAPEUTICS COMMITTEE (ADTC)
2017/18**

New Medicine Product/Device Endorsement Categories

A	Approved for general use - hospital and general practice	Green	Unrestricted General Use Used widely and in accordance with a respectable, responsible body of clinical opinion (e.g. BNF for children; SIGN/NICE recommendation; royal college guidelines)
B	Approved for specialist use only	Amber	General Use With Restrictions (Prescribers to be outlined) Supporting clinical evidence has been evaluated by NHS Borders ADTC/Formulary committee. Local use has peer group support and reflects practice in other NHS Board areas. May require "shared care protocol". (include information here) Specific patient consent not normally required.
C	Approved for consultant initiation, with ongoing prescribing in general practice		
D	Approved for shared care between hospital and general practice. Shared care protocol to be developed. (Information included here)	Red	Specialist Use Only Supporting clinical evidence has been evaluated by NHS Borders ADTC/Formulary committee. Limited evidence of efficacy available. Rarely used or may have serious potential side effects requiring close supervision of treatment Specific patient consent indicated.
E	Not approved (reason given)		
F	No decision – further information required (listed here)	Black	Not Approved for use

NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 12th APRIL 2017		
NMA	Indication	BFC Decision
Insulin aspart (Fiasp)	Treatment of diabetes mellitus in adults.	Category C
Omnican Lance Soft Lancets	Used to get the blood sample to test blood glucose in diabetic patients.	Category A
Unilet Eco Lancets	Used to get the blood sample to test blood glucose in diabetic patients	Category A

Aztreonam (Azactam)	Alternative to carbapenems in treatment of severe infection caused by susceptible Gram negative bacteria on the advice of Consultant Microbiologist.	Category B
Emtricitabine/tenofovir disoproxil (Truvada)	In combination with safer sex practices for pre-exposure prophylaxis to reduce risk of sexually acquired HIV-1 infection in adults at high risk.	Category B
Glucodrate	Dietary management of short bowel-associated intestinal failure and intestinal insufficiency.	Category B
Ixekizumab 80mg solution for injection (Taltz®)	Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.	Category B
Nepafenac 3mg/ml eye drops (Nevenac)	Reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.	Category B

NEW MEDICINE APPLICATIONS BROUGHT TO ADTC MEETING OF 10th MAY 2017

NMA	Indication	ADTC Decision
No applications at this meeting		

NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 14th JUNE 2017

NMA	Indication	BFC Decision
No applications at this meeting		

NEW MEDICINE APPLICATIONS BROUGHT TO ADTC MEETING OF 12th JULY 2017

NMA	Indication	ADTC Decision
Dalteparin	Prophylaxis, treatment and extended treatment of DVT/PE. Full anticoagulation for cardiology indications.	Category A

NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 9th AUGUST 2017

NMA	Indication	BFC Decision
Ustekinumab (Stelara)	Treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist or have medical contraindications to such therapies	Category B

Budesonide/formoterol (Symbicort SMART)	The regular treatment of asthma where use of a combination (inhaled corticosteroid and a long acting β_2 adrenoceptor agonist is appropriate (see application)	Category C
Obeticholic Acid (Ocaliva)	Primary biliary cholangitis (also known as primary biliary cirrhosis) in combination with ursodeoxycholic acid in adults with an inadequate response to ursodeoxycholic acid or as monotherapy in adults unable to tolerate ursodeoxycholic acid	Category B
Ciprofloxacin + Dexamethasone ear drops (Cilodex)	Treatment of following infections in adults and children: Acute otitis media in patients with tympanostomy tubes (AOMT); acute otitis externa	Category B

NEW MEDICINE APPLICATIONS BROUGHT TO ADTC MEETING OF 13th SEPTEMBER 2017

NMA	Indication	ADTC Decision
No applications at this meeting		

NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 11th OCTOBER 2017

NMA	Indication	BFC Decision

NEW MEDICINE APPLICATIONS BROUGHT TO ADTC MEETING OF 8th NOVEMBER 2017

NMA	Indication	ADTC Decision

NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 13th DECEMBER 2017

NMA	Indication	BFC Decision

NEW MEDICINE APPLICATIONS BROUGHT TO ADTC MEETING OF 10th JANUARY 2018

NMA	Indication	ADTC Decision

NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 14th FEBRUARY 2018

NMA	Indication	BFC Decision

NEW MEDICINE APPLICATIONS BROUGHT TO ADTC MEETING OF 14th MARCH 2018

NMA	Indication	ADTC Decision